



Conclusion , Results , type of study

✓ ✓ ✓ ✓ ✓
5, 10, 15, 20, 30, / 50

→ 60, 62

Later , 10 till 62 with Conclusion.

✓ →

✓ → with Docx file

→ Confidence level

when less than 0.5 Flag it.

5

put 5 articles

Conclusion , results , type of study

Extracted Data

	Filename	Confidence	Paper Title	Conclusion
0	1-s2.0-S1878747924000370-main.pdf	0.850000	Commentary Extended interval dosing of natalizumab: More evidence in support	The main findings of the study by Ruggie
1	1-s2.0-S2211034822007022-main.pdf	1.000000	Multiple Sclerosis and Related Disorders 80 (2023) 105151.	The results of our study suggest that hea
2	10.1007/s00415-014-7574-6.pdf	0.900000	Intense immunosuppression for the treatment of an immune reconstitution inflam	IRIS can be a serious manifestation relat
3	1-s2.0-S0022510X21003166-main.pdf	0.900000	Wearing-off symptoms during standard and extended natalizumab dosing intervals: I	Our observations support the need to st
4	1-s2.0-S22110348221006122x-main.pdf	1.000000	Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-	Our study highlights that NTZ reducing ir

Made with ❤ by its Creator.



Search



ENG

IN

22:44
27-12-2025



CAUCAS
NON-CARBONATED FLAVORED WATER

reviewaid-ai.streamlit.app

Extracted Data

	Conclusion	results	type of
0	The main findings of the study by Ruggieri et al. align with previous observational studies. Results from various studies (e.g., NOVA trial, observational studies from TOUCH, Ital. Comm.		
1	The results of our study suggest that healthcare personnel should be aware of the im. Two hundred five patients with MS were recruited, in- cluding 159 women and 46 men; observ		
2	n IRIS can be a serious manifestation related to NTZ treatment interruption and the adi. Patient received 1 g of IV cyclophosphamide followed by a cycle of rituximab, leading Case re		
3	: Our observations support the need to study the effect of EID on wearing-off symptom. At the outbreak of COVID-19, a total of 31 patients were receiving natalizumab at our observ		
4	P Our study highlights that NTZ redosing in pwMS during active SARS-CoV-2 infection is All patients included in the study had at least one symptom of COVID-19 at onset; in p retrospect		

Made with by its' Creator: Score Interpretation

2°C Windy

ENG IN 27-12-2025 22:46

hp



CAUCASIAN
NON-CARBONATED FLAVOUR

(27) WhatsApp ReviewAID / AI Screen & Extra ReviewAID / AI Screen & Extra New tab reviewaid-ai.streamlit.app Fork 🔍


Extracted Data

	results	type of study
0	Ierli et al. align with previous observational stu... Results from various studies (e.g., NOVA trial, observational studies from TOUCH, Ital...	Commentary
1	althcare personnel should be aware of the im... Two hundred five patients with MS were recruited, in- cluding 159 women and 46 me...	observational cross- sectional descriptive study
2	ted to NTZ treatment interruption and the ad... Patient received 1 g of IV cyclophosphamide followed by a cycle of rituximab, leading...	Case report
3	udy the effect of ED on wearing-off symptom... At the outbreak of COVID-19, a total of 311 patients were receiving natalizumab at our i...	observational study
4	In pmMS during active SARS-CoV-2 infection is... All patients included in the study had at least one symptom of COVID-19 at onset; In p...	retrospective

Made with by its.Criatoriance Score Interpretation

PC Windy Search

ENG IN 22:46 27-12-2023



10 articles.

⇒ Can't drag & drop files all together

⇒ Click browse files , Select files &
click open . it is fast .

After 2 paper extracted , taking around
1 minute & processed 10 papers .

	Filename	Confidence	Paper Title
0	bmj_1.html	1.000000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews and meta-analyses
1	1-s2.0-S0032251021003366-main.pdf	0.900000	Wearing-off symptoms during standard and extended natalizumab dosing intervals
2	1-s2.0-S221103482100612X-main.pdf	0.900000	Safety of Natalizumab Infusion in multiple sclerosis patients during active SARS-CoV-2 infection
3	1-s2.0-S1878747924000370-main.pdf	0.900000	Commentary Extended interval dosing of natalizumab: More evidence in support of the safety of this approach
4	1-s2.0-S2211034823067022-main.pdf	0.900000	Multiple Sclerosis and Related Disorders 80 (2023) 105351
5	10.1007/s00415-014-7574-6.pdf	0.900000	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome
6	A real world multi center study on efficacy and safety of natalizumab in Indian patient population.pdf	1.000000	A real world multi center study on efficacy and safety of natalizumab in Indian population
7	Baldazzi et al. - 2019 - How to perform a meta-analysis with R: a practical tutorial.pdf	1.000000	How to perform a meta-analysis with R: a practical tutorial
8	Bernardes et al. - 2024 - Natalizumab extended interval dosing what about wearing-off effect?.pdf	1.000000	Natalizumab extended Interval dosing: what about wearing-off effect?
9	Bigaut et al. - 2023 - Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort.pdf	1.000000	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort

Confidence Score Interpretation

Made with ❤ by its Creator

 STC
Windy



CAUCAS
NON-CARBONATED

reviewaid-ai-streamlit-app

Confidence	Paper Title	Conclusion
0	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	The PRISMA 2020 statement provides updated reporting guidance for systematic r
1	Wearing-off symptoms during standard and extended natalizumab dosing intervals: I	Our observations support the need to study the effect of EID on wearing-off sympt
2	Safety of Natalizumab Infusion in multiple sclerosis patients during active SARS-CoV-	Our data supports the safety of NTZ redosing in these circumstances.
3	Commentary Extended interval dosing of natalizumab: More evidence in support	Overall, the main findings of the study by Ruggieri et al. are in line with previous o
4	Multiple Sclerosis and Related Disorders 80 (2023) 105151	The results of our study suggest that healthcare personnel should be aware of the
5	Intense immunosuppression for the treatment of an immune reconstitution inflam	In the meantime, IRIS can be a serious manifestation related to NTZ treatment int
6	A real world multi center study on efficacy and safety of natalizumab in Indian patien	Natalizumab is a highly effective treatment strategy in Indian patients with MS. Th
7	How to perform a meta-analysis with R: a practical tutorial	It represents a powerful and flexible tool to conduct meta-analyses. This publicati
8	Natalizumab extended interval dosing: what about wearing-off effect?	WO affects a significant proportion of MS patients under natalizumab. Despite clin
9	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort	In our cohort of patients treated with NTZ, poor outcomes were infrequent and an

Confidence Score Interpretation

Made with ❤ by its Creator. Classification Date: 2023-12-27 22:59

hp



15 articles.



0 (2) WhatsApp

Reviewaid / AI Screen & Extr... Reviewaid / AI Screen & Extr... New tab

reviewaid-ai.streamlit.app

Fork

Confidence Score Interpretation

	Confidence	Paper Title	Conclusion
0	1.000000	Wearing-off symptoms during standard and extended natalizumab dosing intervals	Our observations support the need to study the effect of EID on wearing-off symptoms.
1	1.000000	Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection	Our data supports the safety of NTZ dosing in these circumstances.
2	0.900000	Extended interval dosing of natalizumab: More evidence in support	The main findings of the study by Ruggieri et al. are in line with previous observations.
3	1.000000	Multiple Sclerosis and Related Disorders 80 (2023) 105151	The results of our study suggest that healthcare personnel should be aware of the increased risk of MS relapses after discontinuing natalizumab.
4	0.900000	Intense immunosuppression for the treatment of an immune reconstitution illness	IRIS can be a serious manifestation related to NTZ treatment interruption and the associated risk of MS relapses.
5	1.000000	A real world multi center study on efficacy and safety of natalizumab in Indian patients with MS	Natalizumab is a highly effective treatment strategy in Indian patients with MS. The study highlights the importance of continued treatment despite potential side effects.
6	1.000000	How to perform a meta-analysis with R: a practical tutorial	It represents a powerful and flexible tool to conduct meta-analyses. This publication provides a comprehensive guide for researchers.
7	1.000000	Natalizumab extended interval dosing: what about wearing-off effect?	Wearing-off affects a significant proportion of MS patients under natalizumab. Its prevalence, mechanisms, and clinical significance remain to be fully elucidated.
8	1.000000	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort	In our cohort of patients treated with NTZ, poor outcomes were infrequent and are difficult to predict.
9	1.000000	The PRISMA 2020 statement: An updated guideline for reporting systematic reviews	We anticipate that the PRISMA 2020 statement will benefit authors, editors, and peer reviewers in the field of systematic reviews.

Made with ❤️ by Streamlit

5°C Windy

Q Search

HP

23:10 27-12-2025



WhatsApp

reviewaid / AI Scorerai & Est.

Fork

Confidence Score Interpretation

Made with by iir Create

1 1.000000 A real world multi center study on efficacy and safety of natalizumab in Indian patients with MS. The study shows that natalizumab is a highly effective treatment strategy in Indian patients with MS. The study also highlights the safety profile of natalizumab.

2 1.000000 How to perform a meta-analysis with its practical tutorial

3 1.000000 Natalizumab extended interval dosing: what about wearing-off effect?

4 1.000000 Long-term effect of natalizumab in patients with RRMS: TYSER cohort

5 1.000000 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

6 0.960000 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

7 1.000000 Extended interval dosing of natalizumab: a two-center, 3-year experience

8 1.000000 The use of natalizumab for multiple sclerosis

9 1.000000 Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 1 year follow-up

10 1.000000 Similar Clinical Outcomes for Natalizumab Patients Switching to Every-4-Week D

11 1.000000 These analyses of real-world data from TOP demonstrate no significant difference in clinical outcomes between patients who continued natalizumab and those who switched to every-4-week dosing.

12 1.000000 Natalizumab is effective in controlling MS as very few clinical relapses were observed.

13 1.000000 Natalizumab remains an important part of the treatment arsenal for patients with MS.

14 1.000000 In conclusion, markers of disease activity remain low during long-term follow-up of patients receiving natalizumab.

15 0.990000

16 1.000000

17 1.000000

18 1.000000

19 1.000000

20 1.000000

21 1.000000

22 1.000000

23 1.000000

24 1.000000

25 1.000000

26 1.000000

27 1.000000

28 1.000000

29 1.000000

30 1.000000

31 1.000000

32 1.000000

33 1.000000

34 1.000000

35 1.000000

36 1.000000

37 1.000000

38 1.000000

39 1.000000

40 1.000000

41 1.000000

42 1.000000

43 1.000000

44 1.000000

45 1.000000

46 1.000000

47 1.000000

48 1.000000

49 1.000000

50 1.000000

51 1.000000

52 1.000000

53 1.000000

54 1.000000

55 1.000000

56 1.000000

57 1.000000

58 1.000000

59 1.000000

60 1.000000

61 1.000000

62 1.000000

63 1.000000

64 1.000000

65 1.000000

66 1.000000

67 1.000000

68 1.000000

69 1.000000

70 1.000000

71 1.000000

72 1.000000

73 1.000000

74 1.000000

75 1.000000

76 1.000000

77 1.000000

78 1.000000

79 1.000000

80 1.000000

81 1.000000

82 1.000000

83 1.000000

84 1.000000

85 1.000000

86 1.000000

87 1.000000

88 1.000000

89 1.000000

90 1.000000

91 1.000000

92 1.000000

93 1.000000

94 1.000000

95 1.000000

96 1.000000

97 1.000000

98 1.000000

99 1.000000

100 1.000000

101 1.000000

102 1.000000

103 1.000000

104 1.000000

105 1.000000

106 1.000000

107 1.000000

108 1.000000

109 1.000000

110 1.000000

111 1.000000

112 1.000000

113 1.000000

114 1.000000

115 1.000000

116 1.000000

117 1.000000

118 1.000000

119 1.000000

120 1.000000

121 1.000000

122 1.000000

123 1.000000

124 1.000000

125 1.000000

126 1.000000

127 1.000000

128 1.000000

129 1.000000

130 1.000000

131 1.000000

132 1.000000

133 1.000000

134 1.000000

135 1.000000

136 1.000000

137 1.000000

138 1.000000

139 1.000000

140 1.000000

141 1.000000

142 1.000000

143 1.000000

144 1.000000

145 1.000000

146 1.000000

147 1.000000

148 1.000000

149 1.000000

150 1.000000

151 1.000000

152 1.000000

153 1.000000

154 1.000000

155 1.000000

156 1.000000

157 1.000000

158 1.000000

159 1.000000

160 1.000000

161 1.000000

162 1.000000

163 1.000000

164 1.000000

165 1.000000

166 1.000000

167 1.000000

168 1.000000

169 1.000000

170 1.000000

171 1.000000

172 1.000000

173 1.000000

174 1.000000

175 1.000000

176 1.000000

177 1.000000

178 1.000000

179 1.000000

180 1.000000

181 1.000000

182 1.000000

183 1.000000

184 1.000000

185 1.000000

186 1.000000

187 1.000000

188 1.000000

189 1.000000

190 1.000000

191 1.000000

192 1.000000

193 1.000000

194 1.000000

195 1.000000

196 1.000000

197 1.000000

198 1.000000

199 1.000000

200 1.000000

201 1.000000

202 1.000000

203 1.000000

204 1.000000

205 1.000000

206 1.000000

207 1.000000

208 1.000000

209 1.000000

210 1.000000

211 1.000000

212 1.000000

213 1.000000

214 1.000000

215 1.000000

216 1.000000

217 1.000000

218 1.000000

219 1.000000

220 1.000000

221 1.000000

222 1.000000

223 1.000000

224 1.000000

225 1.000000

226 1.000000

227 1.000000

228 1.000000

229 1.000000

230 1.000000

231 1.000000

232 1.000000

233 1.000000

234 1.000000

235 1.000000

236 1.000000

237 1.000000

238 1.000000

239 1.000000

240 1.000000

241 1.000000

242 1.000000

243 1.000000

244 1.000000

245 1.000000

246 1.000000

247 1.000000

248 1.000000

249 1.000000

250 1.000000

251 1.000000

252 1.000000

253 1.000000

254 1.000000

255 1.000000

256 1.000000

257 1.000000

258 1.000000

259 1.000000

260 1.000000

261 1.000000

262 1.000000

263 1.000000

264 1.000000

265 1.000000

266 1.000000

267 1.000000

268 1.000000

269 1.000000

270 1.000000

271 1.000000

272 1.000000

273 1.000000

274 1.000000

275 1.000000

276 1.000000

277 1.000000

278 1.000000

279 1.000000

280 1.000000

281 1.000000

282 1.000000

283 1.000000

284 1.000000

285 1.000000

286 1.000000

287 1.000000

288 1.000000

289 1.000000

290 1.000000

291 1.000000

292 1.000000

293 1.000000

294 1.000000

295 1.000000

296 1.000000

297 1.000000

298 1.000000

299 1.000000

300 1.000000

301 1.000000

302 1.000000

303 1.000000

304 1.000000

305 1.000000

306 1.000000

307 1.000000

308 1.000000

309 1.000000

310 1.000000

311 1.000000

312 1.000000

313 1.000000

314 1.000000

315 1.000000

316 1.000000

317 1.000000

318 1.000000

319 1.000000

320 1.000000

321 1.000000

322 1.000000

323 1.000000

324 1.000000

325 1.000000

326 1.000000

327 1.000000

328 1.000000

329 1.000000

330 1.000000

331 1.000000

332 1.000000

333 1.000000

334 1.000000

335 1.000000

336 1.000000

337 1.000000

338 1.000000

339 1.000000

340 1.000000

341 1.000000

342 1.000000

343 1.000000

344 1.000000

345 1.000000

346 1.000000

347 1.000000

348 1.000000

349 1.000000

350 1.000000

351 1.000000

352 1.000000

353 1.000000

354 1.000000

355 1.000000

356 1.000000

357 1.000000

358 1.000000

359 1.000000

360 1.000000

361 1.000000

362 1.000000

363 1.000000

364 1.000000

365 1.000000

366 1.000000

367 1.000000

368 1.000000

369 1.000000

370 1.000000

371 1.000000

372 1.000000

373 1.000000

374 1.000000

375 1.000000

376 1.000000

377 1.000000

378 1.000000

379 1.000000

380 1.000000

381 1.000000

382 1.000000

383 1.000000

384 1.000000

385 1.000000

386 1.000000

387 1.000000

388 1.000000

389 1.000000

390 1.000000

391 1.000000

392 1.000000

393 1.000000

394 1.000000

395 1.000000

396 1.000000

397 1.000000

398 1.000000

399 1.000000

400 1.000000

401 1.000000

402 1.000000

403 1.000000

404 1.000000

405 1.000000

406 1.000000

407 1.000000

408 1.000000

409 1.000000

410 1.000000

411 1.000000

412 1.000000

413 1.000000

414 1.000000

415 1.000000

416 1.000000

417 1.000000

418 1.000000

419 1.000000

420 1.000000

421 1.000000

422 1.000000

423 1.000000

424 1.000000

425 1.000000

426 1.000000

427 1.000000

428 1.000000

429 1.000000

430 1.000000

431 1.000000

432 1.000000

433 1.000000

434 1.000000

435 1.000000

436 1.000000

437 1.000000

438 1.000000

439 1.000000

440 1.000000

441 1.000000

442 1.000000

443 1.000000

444 1.000000

445 1.000000

446 1.000000

447 1.000000

448 1.000000

449 1.000000

450 1.000000

451 1.000000

452 1.000000

453 1.000000

454 1.000000

455 1.000000

456 1.000000

457 1.000000

458 1.000000

459 1.000000

460 1.000000

461 1.000000

462 1.000000

463 1.000000

464 1.000000

465 1.000000

466 1.000000

467 1.000000

468 1.000000

469 1.000000

470 1.000000

471 1.000000

472 1.000000

473 1.000000

474 1.000000

475 1.000000

476 1.000000

477 1.000000

478 1.000000

479 1.000000

480 1.000000

481 1.000000

482 1.000000

483 1.000000

484 1.000000

485 1.000000

486 1.000000

487 1.000000

488 1.000000

489 1.000000

490 1.000000

491 1.000000

492 1.000000

493 1.000000

494 1.000000

495 1.000000

496 1.000000

497 1.000000

498 1.000000

499 1.000000

500 1.000000

501 1.000000

502 1.000000

503 1.000000

504 1.000000

505 1.000000

506 1.000000

507 1.000000

508 1.000000

509 1.000000

510 1.000000

511 1.000000

512 1.000000

513 1.000000

514 1.000000

515 1.000000

516 1.000000

517 1.000000

518 1.000000

519 1.000000

520 1.000000

521 1.000000

522 1.000000

523 1.000000

524 1.000000

525 1.000000

526 1.000000

527 1.000000

528 1.000000

529 1.000000

530 1.000000

531 1.000000

532 1.000000

533 1.000000

534 1.000000

535 1.000000

536 1.000000

537 1.000000

538 1.000000

539 1.000000

540 1.000000

541 1.000000

542 1.000000

543 1.000000

544 1.000000

545 1.000000

546 1.000000

547 1.000000

548 1.000000

549 1.000000

550 1.000000

551 1.000000

552 1.000000

553 1.000000

554 1.000000

555 1.000000

556 1.000000

557 1.000000

558 1.000000

559 1.000000

560 1.000000

561 1.000000

562 1.000000

563 1.000000

564 1.000000

565 1.000000

566 1.000000

567 1.000000

568 1.000000

569 1.000000

570 1.000000

571 1.000000

572 1.000000

573 1.000000

574 1.000000

575 1.000000

576 1.000000

577 1.000000

578 1.000000

579 1.000000

580 1.000000

581 1.000000

582 1.000000

583 1.000000

584 1.000000

585 1.000000

586 1.000000

587 1.000000

588 1.000000

589 1.000000

590 1.000000

591 1.000000

592 1.000000

593 1.000000

594 1.000000

595 1.000000

596 1.000000

597 1.000000

598 1.000000

599 1.000000

600 1.000000

601 1.000000

602 1.000000

603 1.000000

604 1.000000

605 1.000000

606 1.000000

607 1.000000

608 1.000000

609 1.000000

610 1.000000

611 1.000000

612 1.000000

613 1.000000

614 1.000000

615 1.000000

616 1.000000

617 1.000000

618 1.000000

619 1.000000

620 1.000000

621 1.000000

622 1.000000

623 1.000000

624 1.000000

625 1.000000

626 1.000000

627 1.000000

628 1.000000

629 1.000000

630 1.000000

631 1.000000

632 1.000000

633 1.000000

634 1.000000

635 1.000000

636 1.000000

637 1.000000

638 1.000000

639 1.000000

640 1.000000

641 1.000000

642 1.000000

643 1.000000

644 1.000000

645 1.000000

646 1.000000

647 1.000000

648 1.000000

649 1.000000

650 1.000000

651 1.000000

652 1.000000

653 1.000000

654 1.000000

655 1.000000

656 1.000000

657 1.000000

658 1.000000

659 1.000000

660 1.000000

661 1.000000

662 1.000000

663 1.000000

664 1.000000

665 1.000000

666 1.000000

667 1.000000

668 1.000000

669 1.000000

670 1.000000

671 1.000000

672 1.000000

673 1.000000

674 1.000000

675 1.000000

676 1.000000

677 1.000000

678 1.000000

679 1.000000

680 1.000000

681 1.000000

682 1.000000

683 1.000000

684 1.000000

685 1.000000

686 1.000000

687 1.000000

688 1.000000

689 1.000000

690 1.000000

691 1.000000

692 1.000000

693 1.000000

694 1.000000

695 1.000000

696 1.000000

697 1.000000

698 1.000000

699 1.000000

700 1.000000

701 1.000000

702 1.000000

703 1.000000

704 1.000000

705 1.000000

706 1.000000

<

20 articles

Extracted Data

	Confidence	Paper Title	Conclusion
0	1.000000	a4-integrin receptor desaturation and disease activity return after natalizumab cessation	A faster decline in natalizumab I/O, longer IHO period, and higher T2 LV at baseline.
1	1.000000	Wearing-off symptoms during standard and extended natalizumab dosing intervals: I	Our observations support the need to study the effect of EID on wearing-off symptoms.
2	1.000000	Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-	Our data supports the safety of NTZ redosing in these circumstances.
3	0.900000	Extended interval dosing of natalizumab: More evidence in support	The main findings of the study by Ruggieri et al. are in line with previous observations.
4	1.000000	Multiple Sclerosis and Related Disorders 80 (2023) 105151	The results of our study suggest that healthcare personnel should be aware of this potential side effect.
5	0.900000	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome (IRIS) can be a serious manifestation related to NTZ treatment interruption and discontinuation.	IRIS can be a serious manifestation related to NTZ treatment interruption and discontinuation.
6	1.000000	A real world multi center study on efficacy and safety of natalizumab in Indian patients	Natalizumab is a highly effective treatment strategy in Indian patients with MS.
7	1.000000	Statistics in practice How to perform a meta-analysis with R: a practical tutorial	R represents a powerful and flexible tool to conduct meta-analyses. This publication provides a step-by-step guide for performing meta-analyses using R.
8	1.000000	Natalizumab extended interval dosing: what about wearing-off effect?	WO affects a significant proportion of MS patients under natalizumab. Despite this, the overall efficacy remains high.
9	1.000000	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort	In our cohort of patients treated with NTZ, poor outcomes were infrequent and transient.

Made with ❤️ by its Creator.



5°C
Windy



Q Search



ENG

IN



23:18
27-12-2025

	Confidence	Paper Title	Conclusion
10	1.000000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	We anticipate that the PRISMA 2020 statement will benefit authors, editors, an
11	1.000000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	We anticipate that the PRISMA 2020 statement will benefit authors, editors, an
12	1.000000	Extended Interval dosing of natalizumab: a two-center, 7-year experience	Natalizumab is effective in controlling MS as very few clinical relapses were ob
13	1.000000	The use of natalizumab for multiple sclerosis	Natalizumab remains an important part of the treatment arsenal for patients v
14	1.000000	Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years	Natalizumab is increasingly used earlier in the disease course. Most patients tr
15	0.900000	Similar Clinical Outcomes for Natalizumab Patients Switching to Every-6-Week Dosing	These analyses of real-world data from TDP demonstrate no significant differe
16	1.000000	Clinical effectiveness of different natalizumab interval dosing schedules in a large Ital	The use of NTZ with an extended interval schedule showed similar effectiveness
17	1.000000	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?	In conclusion, there is no evidence of a reduced efficacy of natalizumab in an E
18	1.000000	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Ital	There is no evidence of the reduced efficacy of natalizumab in an EID setting re
19	1.000000	Long-term disease activity and disability progression in relapsing-remitting multiple	The results suggest that starting natalizumab early, during active inflammati

Made with ❤ by its Creator.



Q Search



ENG
IN



2518



27-12-2025



30 Articles.



ReviewAID / AI Screener & Extractor

reviewaid-ai-streamlitapp

Fork ⌂

	Confidence	Paper Title	Conclusion
0	0.900000	Wearing-off symptoms during standard and extended natalizumab dosing intervals: I	Our observations support the need to study the effect of EID on wearing-off syndrome.
1	1.000000	Safety of Natalizumab Infusion in multiple sclerosis patients during active SARS-CoV-2 infection	Our data supports the safety of NTZ redosing in these circumstances.
2	0.900000	Extended interval dosing of natalizumab: More evidence in support	Overall, the main findings of the study by Ruggieri et al. are in line with previous reports.
3	1.000000	Multiple Sclerosis and Related Disorders 80 (2023) 105151	The results of our study suggest that healthcare personnel should be aware of the potential risk of MS relapse after treatment interruption.
4	0.900000	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome (IRIS) associated with natalizumab discontinuation	IRIS can be a serious manifestation related to NTZ treatment interruption and should be managed carefully.
5	1.000000	A real world multi center study on efficacy and safety of natalizumab in Indian patients	Natalizumab is a highly effective treatment strategy in Indian patients with MS.
6	1.000000	How to perform a meta-analysis with R: a practical tutorial	R represents a powerful and flexible tool to conduct meta-analyses. This publication provides a step-by-step guide for performing meta-analyses.
7	1.000000	Natalizumab extended interval dosing: what about wearing-off effect?	Wearing-off effect is a significant proportion of MS patients under natalizumab. Despite clinical improvement, some patients experience a relapse.
8	0.900000	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort	In our cohort of patients treated with NTZ, poor outcomes were infrequent and isolated.
9	0.900000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	The PRISMA 2020 statement provides updated reporting guidance for systematic reviews.

Confidence Score Interpretation

Made with Streamlit by its Creator

5°C Windy

Search

HP

ENG IN 27-12-2025 23:54

ReviewAid / AI Screener & Extractor

reviewaid-aistreamitapp

Confidence Score Interpretation

Made with by its Creator.

5°C Windy

Search

hp

ENG IN 27-12-2023

	Confidence	Paper Title	Conclusion
20	1.000000	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing multiple sclerosis.	We found a numerical difference in the mean number of new or newly enlarging lesions between the two groups.
21	1.000000	Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis.	In this observational, retrospective study of 50 patients who discontinued natalizumab, we found that discontinuing natalizumab led to a significant increase in disease activity.
22	1.000000	Improvement In Cognitive Function as Measured by NeuroTrax in Patients with Relapsing-Remitting Multiple Sclerosis Treated With Natalizumab.	Patients treated with natalizumab demonstrated significant improvement in cognitive function compared to those who did not receive natalizumab.
23	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab in patients with relapsing multiple sclerosis.	In conclusion, pwMS that are able to continue their long-term natalizumab treatment report better quality of life than those who discontinued natalizumab.
24	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab in patients with relapsing multiple sclerosis.	In conclusion, pwMS that are able to continue their long-term natalizumab treatment report better quality of life than those who discontinued natalizumab.
25	1.000000	Translational Neuroimmunology in Multiple Sclerosis	Natalizumab is a highly effective treatment for patients with relapsing forms of multiple sclerosis.
26	1.000000	Disease activity following pregnancy-related discontinuation of natalizumab in MS	Early conception after NTZ discontinuation is associated with a reduced risk of disease activity.
27	1.000000	Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 infection	Adopting an extended interval dosing does not result in significantly different clinical outcomes.
28	1.000000	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuation	As our case highlights, the problem of the disease course after natalizumab discontinuation is not fully resolved.
29	1.000000	Increased Relapse Activity for Multiple Sclerosis Natalizumab Users Who Become Noncompliant	Findings suggest that real-world persistent natalizumab users who become noncompliant may experience increased relapse activity.

	Confidence	Paper Title	Conclusion
10	1.000000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	We anticipate that the PRISMA 2020 statement will benefit authors, editors, and
11	1.000000	Extended interval dosing of natalizumab: a two-center, 7-year experience	Natalizumab is effective in controlling MS as very few clinical relapses were obse
12	1.000000	The use of natalizumab for multiple sclerosis	Natalizumab remains an important part of the treatment arsenal for patients wit
13	i 1.000000	Natalizumab treatment of multiple sclerosis -- a Danish nationwide study with 13 years	Natalizumab is increasingly used earlier in the disease course. Most patients tre
14	1.000000	Similar Clinical Outcomes for Natalizumab Patients Switching to Every-6-Week Dosing	These analyses of real-world data from TOP demonstrate no significant differen
15	i 1.000000	Clinical effectiveness of different natalizumab interval dosing schedules in a large Ital	In our retrospective multicentre study, EID does not appear to statistically dimi
16	1.000000	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?	In conclusion, there is no evidence of a reduced efficacy of natalizumab in an EID
17	i 1.000000	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Ital	There is no evidence of the reduced efficacy of natalizumab in an EID setting reg
18	1.000000	Clinical trial Long-term disease activity and disability progression in relapsing-remit	In this longitudinal cohort study of natalizumab treated patients, a higher than e
19	1.000000	αv-Integrin receptor desaturation and disease activity return after natalizumab cessat	A faster decline in natalizumab RO, longer WO period, and higher T2 LV at baseline

Confidence Score Interpretation

Made with by its Creator



5°C
Windy



 Search



2017-12-202



50 articles

error Chy Ai response received

Warn: Re extraction was not able.

Success & Re extraction was succ.

Pg 24 34 → 0.5

36 → 0.6, No Conclusion.

	Confidence	Paper Title	Conclusion
0	1.000000	Wearing-off symptoms during standard and extended natalizumab dosing intervals:	Our observations support the need to study the effect of EID on wearing-off symptoms.
1	0.900000	Safety of Natalizumab Infusion in multiple sclerosis patients during active SARS-CoV-2 infection	Our data supports the safety of NTZ redosing in these circumstances.
2	0.900000	Extended interval dosing of natalizumab: More evidence in support	The main findings of the study by Ruggieri et al. are in line with previous observations.
3	1.000000	Efficacy & Safety of Natalizumab's Extended Interval Dosing in Relapsing Remitting MS	Administration of natalizumab in an EID regimen maintains therapeutic efficacy.
4	1.000000	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome (IRIS) in multiple sclerosis	IRIS can be a serious manifestation related to NTZ treatment interruption and it should be managed.
5	1.000000	A real world multi center study on efficacy and safety of natalizumab in Indian patient population	Natalizumab is a highly effective treatment strategy in Indian patients with MS.
6	1.000000	How to perform a meta-analysis with R: a practical tutorial	R represents a powerful and flexible tool to conduct meta-analyses. This publication is a valuable resource for researchers.
7	1.000000	Natalizumab extended interval dosing: what about wearing-off effect?	WO affects a significant proportion of MS patients under natalizumab. Despite continued dosing, WO may occur.
8	0.900000	Long-term effect of natalizumab in patients with RRMS: TYSTEN cohort	In our cohort of patients treated with NTZ, poor outcomes were infrequent and isolated.
9	1.000000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	We anticipate that the PRISMA 2020 statement will benefit authors, editors, and readers of systematic reviews.

Confidence Score Interpretation

Made with by its Creator.



5°C



 Search



END
IN



00312

	Confidence	Paper Title	Conclusion
10	1.000000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	The PRISMA 2020 statement provides updated reporting guidance for systematic reviews.
11 ✓	1.000000	Extended Interval dosing of natalizumab: a two-center, 7-year experience	Natalizumab is effective in controlling MS as very few clinical relapses were observed.
12	1.000000	The use of natalizumab for multiple sclerosis	Natalizumab remains an important part of the treatment arsenal for patients with MS.
13 ↗	1.000000	Natalizumab treatment of multiple sclerosis — a Danish nationwide study with 13 years of follow-up	Natalizumab is increasingly used earlier in the disease course. Most patients treated with natalizumab remain in remission.
14 ✅	0.900000	Similar Clinical Outcomes for Natalizumab Patients Switching to Every-6-Week Dosing	These analyses of real-world data from TOP demonstrate no significant difference in clinical outcomes between patients who switch to every-6-week dosing and those who remain on every-4-week dosing.
15 ⚡	1.000000	Clinical effectiveness of different natalizumab interval dosing schedules in a large Italian cohort	In our retrospective multicentre study, EID does not appear to statistically differ between patients receiving every 4 weeks or every 6 weeks.
16 ⚡	1.000000	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?	Our study shows that clinical MS reactivation does not occur more frequently in patients extending the interval of natalizumab dosing.
17 ✅	1.000000	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study	There is no evidence of the reduced efficacy of natalizumab in an EID setting compared to standard dosing.
18 ✅	0.900000	Clinical trial Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis after discontinuation of natalizumab	In this longitudinal cohort study of natalizumab-treated patients, a higher rate of relapses was observed after discontinuation of natalizumab.
19 ✅	1.000000	α4-integrin receptor desaturation and disease activity return after natalizumab cessation	A faster decline in natalizumab RDI, longer WO period, and higher T2 LV at baseline.

Confidence Score Interpretation

Made with ❤ by its Creator.



5°C
Windy



00:12



IN



28-12-2025



	Confidence	Paper Title	Conclusion
20 ..	0.900000	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-wk dosing in patients with relapsing multiple sclerosis.	We found a numerical difference in the mean number of new or newly enlarging lesions.
21 v	1.000000	Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis.	In this observational, retrospective study of 50 patients who discontinued natalizumab, we found that discontinuing natalizumab was associated with a significant increase in disease activity.
22 >	1.000000	Improvement in Cognitive Function as Measured by NeuroTrax In Patients with Relapsing Multiple Sclerosis	Patients treated with natalizumab demonstrated significant improvement in cognitive function compared to those who did not receive natalizumab.
23 n	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab in patients with relapsing multiple sclerosis.	Continuous natalizumab treatment provides long-term stability or improvement in patient-reported outcomes.
24 n	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab in patients with relapsing multiple sclerosis.	In conclusion, pwMS that are able to continue their long-term natalizumab treatment report better outcomes.
25 z	1.000000	Translational Neuroimmunology in Multiple Sclerosis	Natalizumab is a highly effective treatment for patients with relapsing forms of multiple sclerosis.
26 t	1.000000	Disease activity following pregnancy-related discontinuation of natalizumab in MS	Early conception after NTZ discontinuation is associated with a reduced risk of clinical relapse.
27 i	1.000000	Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 infection	Adopting an extended interval dosing does not result in significantly different or more frequent wearing-off symptoms.
28 .	1.000000	Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuation	Further studies are required to assess disease course after natalizumab discontinuation.
29 .	1.000000	Increased Relapse Activity for Multiple Sclerosis Natalizumab Users Who Become Noncompliant	Findings suggest that real-world persistent natalizumab users who become noncompliant experience increased relapse activity.

Confidence Score Interpretation

Made with ❤️ by its Creator.



5°C
Windy



Search



ENG IN 00:12 28-12-2025

	Confidence	Paper Title	Conclusion
30	n 0.900000	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients	a 'rebound' pattern was not identified in our cohort, though the disease activity
31	r 1.000000	Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis Treatment Registry	In line with real world data available so far, we confirm in a nationwide Austrian
32	n 1.000000	Natalizumab reduces loss of gray matter and thalamic volume in patients with relapsing-remitting multiple sclerosis	These analyses represent the first placebo-controlled evidence supporting a role
33	0.900000	Natalizumab related progressive multifocal leukoencephalopathy	In the absence of an effective treatment for PML, early detection of the disease is
34	d 0.500000	threshold improvement in MSWS-12 and in Timed Up and Go (TUG) speed, and mean	This post-hoc pooled analysis strengthens evidence that PR-FAM produces clinic
35	s 1.000000	A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis	It seems that using 3 or 6 mg/kg every 4 weeks is the best method of administer
36	0.600000	The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies	Not Found
37	1.000000	Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy	Knowledge of post-DMT relapse and disability progression rates and predictors
38	1.000000	Short communication Massive Intracerebral Epstein-Barr virus reactivation in lethal neuroinflammation	It is proposed that the hyper-inflammatory CD8+ T-cell dominated response ob
39	1.000000	Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as post-transplant complication	These findings confirm and extend the results obtained in another case of post-

Confidence Score Interpretation

Made with ❤ by its Creator.



5°C
Windy



Search



ENG

IN

0013

28-12-2025



	Confidence	Paper Title	Conclusion
40	1.000000	Natalizumab discontinuation in a Dutch real-world cohort	JCV positivity seems the most frequent reason for natalizumab discontinuation.
41	1.000000	Multiple Sclerosis and Related Disorders 51 (2021) 102991	MSST requires only a smartphone to obtain digital biomarkers related to severa
42 p	1.000000	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclero	Natalizumab reduced the risk of the sustained progression of disability and the
43 i	1.000000	An update on the use of natalizumab in the treatment of multiple sclerosis: appropri	Natalizumab is a highly effective and well-tolerated therapy for patients with ac
44 n	1.000000	Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclero	In conclusion, long-term therapy with natalizumab in an EID setting following as
45 >	1.000000	Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomize	No significant differences were observed in change from baseline to week 72 be
46	1.000000	Rayyan—a web and mobile app for systematic reviews	Rayyan is responsive and intuitive in use with significant potential to lighten the
47	1.000000	Natalizumab extended-interval dosing in a real-life setting	Switching from a four-week to a six-week dosing of natalizumab did not increase
48	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with n	pwMS that are able to continue their long-term natalizumab treatment have imp
49 R	1.000000	What to expect after natalizumab cessation in a real-life setting	Our data suggest that rebound of MS disease activity affects a subgroup of patie

Confidence Score Interpretation

Made with  by its Creator.

5°C
Windy



ENG IN  28-12-2025 



Conclusion
36 -> Not found.
becuz there is no full text

downloaded 48 articles
from Research gate.

till page 5.

Search term "Natalizumab"

100 articles

old folder \rightarrow full 60


form "New articles"

fill "pediatric-onset

multiple sclerosis treatment"

40 articles

$$60 + 40 = 100$$




Extracted Data

	Confidence	Paper Title	Conclusion
0	0.900000	Weaning-off symptoms during standard and extended natalizumab dosing intervals I: Our observations support the need to study the effect of ITZ on weaning-off syndromes.	Our observations support the need to study the effect of ITZ on weaning-off syndromes.
1	0.900000	Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection.	Our data supports the safety of ITZ reducing its peaks during active SARS-CoV-2 infection.
2	0.900000	Commentary Extended interval dosing of natalizumab: More evidence in support of the concept.	Overall, the main findings of the study by Ruggieri et al. are in line with previous reports.
3	1.000000	Multiple Sclerosis and Related Disorders 90 (2020) 105151	The results of our study suggest that healthcare personnel should be aware of the potential risks associated with ITZ treatment interruption and the development of MS relapses.
4	1.000000	Intense immunosuppression for the treatment of an immune reconstitution inflammatory syndrome (IRIS) in multiple sclerosis.	IRIS can be a serious manifestation related to ITZ treatment interruption and the development of MS relapses.
5	1.000000	A real-world multi-center study on efficacy and safety of natalizumab in Indian patients with MS.	Natalizumab is a highly effective treatment strategy in Indian patients with MS. It is safe and well-tolerated.
6	1.000000	How to perform a meta-analysis with R: a practical tutorial.	R represents a powerful and flexible tool to conduct meta-analyses. This publication provides a step-by-step guide for performing meta-analyses using R.
7	1.000000	Natalizumab extended interval dosing: what about weaning-off effect?	ITZ represents a significant proportion of MS patients under natalizumab. Despite ITZ being a potent immunosuppressive agent, it may have a weaning-off effect.
8	1.000000	Long-term effect of natalizumab in patients with MS: TYSSEN cohort.	In our cohort of patients treated with ITZ, poor outcomes were infrequent and a long-term benefit was observed.
9	1.000000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews and meta-analyses.	We anticipate that the PRISMA 2020 statement will benefit authors, editors, and readers of systematic reviews and meta-analyses.

Made with by its Creator.

PC Weekly Q Search

hp



Extracted Data

	Confidence	Paper Title	Conclusion
10	0.900000	The PRISMA 2020 statement: an updated guideline for reporting systematic reviews	The PRISMA 2020 statement provides updated reporting guidance for systematic
11	1.000000	Extended Interval dosing of natalizumab: a two-center, 7-year experience	Natalizumab is effective in controlling MS as very few clinical relapses were obse
12	1.000000	The use of natalizumab for multiple sclerosis	Natalizumab remains an important part of the treatment arsenal for patients wit
13	1.000000	Natalizumab treatment of multiple sclerosis – a Danish nationwide study with 13 ye	In conclusion, markers of disease activity remain low during long-term follow-up
14	1.000000	Similar Clinical Outcomes for Natalizumab Patients Switching to Every-6-Week Dosing	These analyses of real-world data from TOP demonstrate no significant differenc
15	0.900000	Clinical effectiveness of different natalizumab interval dosing schedules in a large Ital	In our retrospective multicentre study, EID does not appear to statistically dimini
16	1.000000	Extending the interval of Natalizumab Dosing: Is Efficacy Preserved?	Our study shows that clinical MS reactivation does not occur more frequently in
17	1.000000	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Ital	Our study corroborates data from previous investigations [6,7,11], that EID of int
18	1.000000	Clinical trial Long-term disease activity and disability progression in relapsing-remiti	In this longitudinal cohort study of natalizumab treated patients, a higher than e
19	1.000000	α4-integrin receptor desaturation and disease activity return after natalizumab cessar	A faster decline in natalizumab RO, longer IWO period, and higher T2 LV at baseline

Made with ❤ by its Creator.



Search



ENG

IN

01:12

28-12-2025





ReviewAID / AI Screener & Extractor

reviewaid-ai.streamlitapp/#ui-text-data-extractor

Fork ⚙️

Extracted Data

	Confidence	Paper Title	Conclusion
20	0.900000	Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-wk dosing in patients with multiple sclerosis.	We found a numerical difference in the mean number of new or newly enlarging lesions between the two groups.
21	1.000000	Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis.	In this observational, retrospective study of 50 patients who discontinued natalizumab, we found that discontinuing natalizumab led to a significant increase in disease activity, which was partially prevented by restarting natalizumab.
22	1.000000	Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing-Remitting Multiple Sclerosis Treated With Nata	Patients treated with natalizumab demonstrated significant improvement in cognitive function compared to those who discontinued natalizumab.
23	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab in patients with multiple sclerosis.	Continuous natalizumab treatment provides long-term stability or improvement in patient-reported outcomes.
24	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with natalizumab in patients with multiple sclerosis.	In conclusion, pMS that are able to continue their long-term natalizumab treatment experience improved patient-reported outcomes.
25	1.000000	Translational Neuroimmunology in Multiple Sclerosis	Natalizumab is a highly effective treatment for patients with relapsing forms of MS.
26	1.000000	Disease activity following pregnancy-related discontinuation of natalizumab in MS	Early conception after NTZ discontinuation is associated with a reduced risk of disease relapse.
27	1.000000	Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 infection	Adopting an extended interval dosing does not result in significantly different rates of disease relapse.
28	0.900000	Recurrent disease activity rebound in a patient with multiple sclerosis after natalizumab discontinuation	As our case highlights, the problem of the disease course after natalizumab discontinuation is not fully resolved.
29	1.000000	Increased Relapse Activity for Multiple Sclerosis Natalizumab Users Who Become Noncompliant	The results of this study suggest that real-world persistent natalizumab users who become noncompliant may experience increased relapse activity.

Made with ❤️ by its Creator.

5°C Windy

Q Search

hp

ENG IN 01:13 28-12-2025



Reviewaid / AI Screenlet & Extractor

reviewaid-al-streamlit-app/full-text-data-extractor

Extracted Data

	Confidence	Paper Title	Conclusion
30	1.000000	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients	In conclusion, a 'rebound' pattern was not identified in our cohort, though the d...
31	1.000000	Real-world use of natalizumab in Austria: data from the Austrian Multiple Sclerosis T...	In Austria with real world data available so far, we confirm in a nationwide Austrian r...
32	1.000000	Natalizumab reduces loss of gray matter and thalamic volume in patients with relaps...	These analyses represent the first placebo-controlled evidence supporting a role o...
33	0.900000	Natalizumab related progressive multifocal leukoencephalopathy	In the absence of an effective treatment for PM, early detection of the disease is...
34	0.900000	DOES SOCIOECONOMIC STATUS IMPACT ON THE PRESCRIPTION OF DISEASE-MODIFYING DRUGS (DM...	SES was not predictive of prescription of DMTs in this single-centre study. It wou...
35	1.000000	A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple s...	It seems that using 3 or 6 mg/kg every 4 weeks is the best method of administrat...
36	1.000000	Predictors of relapse and disability progression in MS patients who discontinue dise...	Knowledge of post-DMT relapse and disability progression rates and predictors can h...
37	0.900000	Short communication Massive intracerebral Epstein-Barr virus reactivation in relapse r...	It is proposed that the hyper-inflammatory CD4+ T-cell dominated response observed i...
38	1.000000	Epstein-Barr virus-associated immune reconstitution inflammatory syndrome as a pos...	These findings confirm and extend the results obtained in another case of post-infe...
39	1.000000	Natalizumab discontinuation in a Dutch real-world cohort	JCV positivity seems the most frequent reason for natalizumab discontinuation,...

Made with ❤ by its Creator.

SVC Windy

Q Search

hp

ENGLISH

2023-12-26



ReviewAI / AI Screen & Extractor

reviewaid-aistreamitapp/FMLL-test-data-extractor

Fork |

40	1.000000	Multiple Sclerosis and Related Disorders 53 (2021) 362991	MSLT requires only a smartphone to obtain digital biomarkers related to several
41	1.000000	A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Scler	Natalizumab reduced the risk of the sustained progression of disability and the
42	1.000000	An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate	Natalizumab is a highly effective and well-tolerated therapy for patients with act
43	1.000000	Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Scler	In conclusion, long-term therapy with natalizumab in an ED setting following an
44	1.000000	Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized	Our results support the findings of the primary and secondary magnetic reson
45	1.000000	Rayyan—a web and mobile app for systematic reviews	Rayyan is responsive and intuitive in use with significant potential to facilitate the
46	1.000000	Natalizumab extended-interval dosing in a real-life setting	Switching from a four-week to a six-week dosing of natalizumab did not increase
47	1.000000	Patient-reported outcomes based on discontinuation or continuous treatment with r	patients that are able to continue their long-term natalizumab treatment have imp
48	1.000000	What to expect after natalizumab cessation in a real-life setting	Our data suggest that rebound of MS disease activity affects a subgroup of patie
49	0.950000	Comparative efficacy of switching to natalizumab in active multiple sclerosis	Using large, real-world, propensity-matched datasets we demonstrate that after

Confidence Score Interpretation

Made with by its Creator Classification Description

3PC Only

Q Search

HP

05:14 26-12-2025



ReviewAid / AI Screener & Extractor

reviewaid-ai.streamlit.app/#/ai-text-data-extractor

Extracted Data

	Confidence	Paper Title	Conclusion
50	1.000000	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis	In this study, NTZ induced a reduction of a wide spectrum of basic CSF inflammatory markers.
51	1.000000	Randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis	In conclusion, natalizumab 300 mg SC Q4W was comparable to standard 300 mg SC Q2W.
52	0.600000	aNfL applicability as additional monitoring tool in natalizumab extended interval dosing	Not Found
53	1.000000	The majority of natalizumab-treated MS patients have high natalizumab concentrations	In conclusion, the large majority (54%) of NTZ patients have high NTZ trough concentrations.
54	1.000000	Personalized extended interval dosing of natalizumab in MS - a prospective multicenter study	Personalized extended interval dosing did not induce recurrence of MS disease.
55	0.900000	Using prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition	The global prevalence of MS has risen since 2013, but good surveillance data is limited.
56	0.000000	Not Found	Not Found
57	1.000000	Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy	A detailed review of possible cases of PML in patients exposed to natalizumab for MS.
58	0.600000	TESI DOCTORAL: BRAIN VOLUME AND BRAIN METABOLITE CHANGES IN THE FIRST STAGE OF MS	Not Found
59	0.000000	Not Found	Not Found

Made with by ReviewAid


Place Score Interpretation

5°C Windy

Search

hp





ReviewPad / AI Screen & Extractor

reviewpad-ai.streamlitapp.svc-ingress.kube-system.ingress.kube-system

Extracted Data


Filename	Confidence	Paper Title
50 Subramanian et al. - 2021 - Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis	1.000000	Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
51 Trojano et al. - 2021 - A randomized study of natalizumab dosing regimens for relapsing-remitting multiple sclerosis: applicability as additional monitoring tool in natalizumab-treated patients	1.000000	Randomized study of natalizumab-dosing regimens for relapsing-remitting multiple sclerosis: applicability as additional monitoring tool in natalizumab-treated patients
52 Valentino et al. - 2022 - MRI applicability as additional monitoring tool in natalizumab	0.000000	
53 van Kempen et al. - 2018 - The majority of natalizumab-treated MS patients have high natalizumab concentrations	1.000000	The majority of natalizumab-treated MS patients have high natalizumab concentrations
54 van Kempen et al. - 2020 - Personalized extended interval dosing of natalizumab in MS	1.000000	Personalized extended interval dosing of natalizumab in MS - a prospective multicenter study
55 Walton et al. - 2020 - Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, 1990-2018	1.000000	Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, 1990-2018
56 www.clinicalkey.com.html	0.000000	Not Found
57 Yousry et al. - 2006 - Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy	1.000000	Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
58 Yousefi Benitošić and Ivačka MU FN Brno - 2015 - Brain volume and brain metabolism in MS	0.000000	TESI DOCTORAL BRAIN VOLUME AND BRAIN METABOLITE CHANGES IN THE FIRST
59 Ziemssen et al. - 2015 - Optimizing therapy early in multiple sclerosis: An evidence-based approach	0.000000	Not Found

Made with [CvPR-Extractor](#) Score Interpretation

HP

85.5 28-12-2023





reviewid-streamlit.app/full-text-data-extractor

Extracted Data

	Confidence	Paper Title	Conclusion
60	0.900000	Risk phenotype for MOGAD, although one was diagnosed with a likely parainfectious	A CSF-restricted MOG-IgG profile is rare, with over half of these patients having a
61	1.000000	Genetic polymorphisms and adverse effects that affect the natalizumab clinical response	Poor responsiveness to natalizumab has been linked to the homozygous CC genotype.
62	1.000000	Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	S1P-RM-associated PML shows reduced MS risk but higher post-treatment MS
63	1.000000	Natalizumab Treatment Continuum in NMOS: A Systematic Review and Meta-Analysis	This review demonstrates a substantial 41.7% relapse risk within 12 months of r
64	1.000000	Comparative Efficacy of Ustekinumab Versus Natalizumab in the Treatment of Relapsing	Ustekinumab and natalizumab are both highly effective in managing NMOS, signifi
65	1.000000	A comparison of JC virus assay performance provided with originator and biosimilar	These observed differences create uncertainty in how to counsel patients and in
66	0.900000	A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis	Both medications strongly suppress MMF events and, in the short term, the risks
67	1.000000	Argentina Access, satisfaction, adherence and safety to subcutaneous natalizumab: a cross-sectional study	We found a high rate of change to sCD from MMF, associated with a higher access to
68	1.000000	Analisi di impatto del biosimilare di natalizumab sulla spesa farmaceutica per il trattamento della sclerosi multipla	Considering the results of this budget impact analysis, it is realistic to expect the
69	0.900000	Ciclosporine tablets after treatment with natalizumab (CADMNA-4) - rationale and dosing	The CADMNA trial will generate data regarding the safety, efficacy, and licensure

Made with by on GitHub Score Interpretation

PC: Wendy

HP

10:15 26-12-2025



ReviewAI / AI Screener & Extractor

reviewaid-alstremitapp/full-text-data-extractor

Extracted Data

	Confidence	Paper Title	Conclusion
70	1.000000	Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV IgM	STRATIFY and IMMUNOWELL demonstrate a high level of agreement in the detection of anti-JCV IgM.
71	1.000000	Comparative immunogenicity assessment of biosimilar natalizumab to its reference product	The immunogenicity profile of biosim-NTZ was confirmed to match that of ref-N
72	1.000000	Cost-effectiveness of different treatment strategies with natalizumab for pregnant women	Continuing natalizumab treatment throughout pregnancy is the most cost-effective strategy.
73	1.000000	Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments for MS	To our knowledge, this is the first CCA to assess in detail all effects associated with natalizumab.
74	1.000000	Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab	Administering natalizumab subcutaneously rather than intravenously to treat MS is cost-minimizing.
75	1.000000	Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy	Continuing natalizumab during pregnancy after week 30 decreases the relapse risk.
76	1.000000	Disease Course in Patients Switched from Natalizumab to Alemtuzumab: An Italian Network Study	Our study showed that the use of ALEM as exit strategy was safe and efficacious; however, further studies are needed to confirm these findings.
77	1.000000	Effect of Natalizumab on sIgM and sGFP Levels in Multiple Sclerosis Patients	In conclusion, our data show that an early decrease in sIgM and sGFP values can be observed in patients with MS treated with natalizumab.
78	1.000000	Evaluating natalizumab first-line and later-line use in multiple sclerosis: a US claims analysis	In a real-world setting, initiating natalizumab as a 1L treatment for individuals with MS is cost-effective.
79	1.000000	Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualization of Dosing	Body mass index and dosing interval are the main variables found to influence the pharmacokinetics of natalizumab.

Made with AI by itsCristian | Score Interpretation

3°C Windy

Q search

hp

ENG IN 01:56 26-12-2025

ReviewAid / AI Screener & Extractor

reviewaid-ai.streamlit.app/#full-text-data-extractor

Extracted Data

	Confidence	Paper Title	Conclusion
80	1.000000	Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis	A small but significant decrease in productivity, partially attributed to the COVID-19 pandemic.
81	1.000000	In vitro morphological profiling of T cells predicts clinical response to natalizumab therapy	Our study thus unveils that CD6+ T cells from individual MS patients display heterogeneous morphological profiles.
82	1.000000	Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis	Patients with MS using natalizumab showed decreased connectivity in some regions.
83	1.000000	Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis patients	In conclusion, our findings suggest that the mechanisms of motor fatigue during natalizumab treatment are complex and involve multiple pathways.
84	0.800000	Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the Future	Not Found
85	1.000000	John Cunningham Virus seroconversion during natalizumab treatment	Knowing how to monitor the anti-JCV antibody index and treatment approaches is crucial for managing this complication.
86	1.000000	Low natalizumab trough concentrations are associated with reduced seroconversion	The seroconversion rate observed in patients with MS is low, even at low trough concentrations.
87	1.000000	Disease Progression in Pregnant Women with Relapsing-Remitting Multiple Sclerosis	First and foremost, we emphasize that all our findings are based on observational studies.
88	1.000000	Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell subsets in patients treated with natalizumab or fumarates	Anti-natalizumab antibodies were prevalent in MS patients, although their exact mechanism remains unclear.
89	1.000000	Natalizumab Immunogenicity in Multiple Sclerosis: Evaluating Antibody Development	Anti-natalizumab antibodies were prevalent in MS patients, although their exact mechanism remains unclear.

Made with  by its Creator

Score Interpretation

STC Windy

Search

HP

01:17
28-12-2025

Extracted Data

Filename	Confidence	Paper Title
80 Impact_of_Natalizumab_on_Productivity_and_Ability_.pdf	1.000000	Impact of Natalizumab on Productivity and Ability to Work in Patients with Multiple Sclerosis
81 In_vitro_morphological_profiling_of_T_cells_predic.pdf	1.000000	In vitro morphological profiling of T cells predicts clinical response to natalizumab
82 Influence_of_natalizumab_on_resting-state_connecti.pdf	1.000000	Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
83 Insight_into_motor_fatigue_mechanisms_in_natalizum.pdf	1.000000	Insight into motor fatigue mechanisms in natalizumab treated multiple sclerosis
84 Introducing_the_Biosimilar_Paradigm_to_Neurology_T.pdf	0.600000	Introducing the Biosimilar Paradigm to Neurology: The Totality of Evidence for the Use of Biosimilars in Multiple Sclerosis
85 John_Cunningham_Virus_seropositivity_during_natali.pdf	1.000000	John Cunningham Virus seropositivity during natalizumab treatment
86 Low_natalizumab_trough_concentrations_are_associat.pdf	1.000000	Low natalizumab trough concentrations are associated with reduced seroconversion
87 Natalizumab.pdf	1.000000	Disease Progression in Pregnant Women with Relapsing-Remitting Multiple Sclerosis
88 Natalizumab_and_fumarate_treatment_differentially_.pdf	1.000000	Natalizumab and fumarate treatment differentially modulate CD4+ T cell and B cell responses
89 Natalizumab_Immunogenicity_in_Multiple_Sclerosis_E.pdf	1.000000	Natalizumab Immunogenicity in Multiple Sclerosis: Evaluating Antibody Development

Made with  by its Creator5°C
Windy

Search



ENG

IN



01:17

28-12-2025





Extracted Data

	Confidence	Paper Title	Conclusion
89	1.000000	Natalizumab Immunogenicity in Multiple Sclerosis: Evaluating Antibody Development	Anti-natalizumab antibodies were prevalent in MS patients, although their exact route of entry remains unclear. Routine use of such an assay would enable a better understanding of the safety profile of natalizumab.
90	1.000000	Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis	This study confirms that a large number of biomarker candidates relevant for MS diagnosis and monitoring can be detected in breastmilk.
91	0.900000	Natalizumab promotes anti-inflammatory and repair effects in multiple sclerosis	Cessation of natalizumab mandates appropriate therapeutic bridging and vigilance for progressive multifocal leukoencephalopathy (PML).
92	1.000000	Images in Clinical Neurology Natalizumab Rebound in Multiple Sclerosis	Cessation of natalizumab mandates appropriate therapeutic bridging and vigilance for progressive multifocal leukoencephalopathy (PML).
93	0.900000	Images in Clinical Neurology Natalizumab Rebound in Multiple Sclerosis	Cessation of natalizumab mandates appropriate therapeutic bridging and vigilance for progressive multifocal leukoencephalopathy (PML).
94	0.900000	Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Intestine	Our study shows that circulating integrin $\beta 1 +$ memory CD4 T cells of patients with MS have a proinflammatory phenotype.
95	0.900000	Natalizumab-associated progressive multifocal leukoencephalopathy	The use of natalizumab in the treatment of RRMS leads to an increased risk of developing progressive multifocal leukoencephalopathy (PML).
96	1.000000	Natalizumab-Associated Progressive Multifocal Leukoencephalopathy After Natalizumab Discontinuation	Although natalizumab EIO is expected to lower the risk of developing PML, its efficacy in the treatment of RRMS is well established.
97	1.000000	ADIS BIOSIMILAR BRIEF P0006: A Natalizumab Biosimilar	The role of reference natalizumab in the management of RRMS is well established.
98	1.000000	Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab and fingolimod	Both natalizumab and fingolimod showed high and sustained efficacy in controlling disease activity in pediatric-onset MS.

Made with by [J.W. Cristofari](#): [Source Score Interpretation](#)

SFC
Windy



01:18
ENG
IN
28-12-2025

